Clinical failure of nanoparticles in cancer: mimicking nature's solutions.

The use of nanotechnology has become a promising approach in the treatment of cancer. However, most intravenously injected nanoparticles (NPs) do not effectively reach the tumor mass due to the biological barriers in the body. In an attempt to unify clinical criteria and basic research, we have collected the latest studies and described novel alternatives such as the use of NPs covered with cell membranes to increase NP delivery efficiency. Furthermore, we focus on the prospect of using the cell's natural messengers, exosomes, as vehicles to transport anti-cancer agents and we discuss the technical complications involved. Finally, we propose novel approaches to produce engineered exosomes which may overcome such technical limitations in order to achieve a proper anti-cancer nanotherapy.

[1]  Fan Zhang,et al.  Highly biocompatible zwitterionic phospholipids coated upconversion nanoparticles for efficient bioimaging. , 2014, Analytical chemistry.

[2]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[3]  V. Palanisamy,et al.  Horizontal transfer of RNAs: exosomes as mediators of intercellular communication , 2012, Wiley interdisciplinary reviews. RNA.

[4]  Peixuan Guo,et al.  Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy. , 2018, Cancer letters.

[5]  Yongjiang Zheng,et al.  Exosome-Based Cancer Therapy: Implication for Targeting Cancer Stem Cells , 2017, Front. Pharmacol..

[6]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[7]  T. Xia,et al.  Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.

[8]  Shuming Nie,et al.  Understanding and overcoming major barriers in cancer nanomedicine. , 2010, Nanomedicine.

[9]  S. Tenzer,et al.  Oligodendrocytes secrete exosomes containing major myelin and stress‐protective proteins: Trophic support for axons? , 2007, Proteomics. Clinical applications.

[10]  D. Simberg,et al.  Nanoparticle transport pathways into tumors , 2018, Journal of Nanoparticle Research.

[11]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Biao Lu,et al.  Development of exosome surface display technology in living human cells. , 2016, Biochemical and biophysical research communications.

[13]  Shuai Liu,et al.  Virus Spike and Membrane-Lytic Mimicking Nanoparticles for High Cell Binding and Superior Endosomal Escape. , 2018, ACS applied materials & interfaces.

[14]  E. Graves,et al.  Theranostic nanoparticles enhance the response of glioblastomas to radiation , 2019, Nanotheranostics.

[15]  S. Krishnan,et al.  Nanoparticle-mediated hyperthermia in cancer therapy. , 2011, Therapeutic delivery.

[16]  Myung Soo Kim,et al.  Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[17]  Hui-zhen Jia,et al.  Cancer-targeted functional gold nanoparticles for apoptosis induction and real-time imaging based on FRET. , 2014, Nanoscale.

[18]  Jennifer C Jones,et al.  Efficient production and enhanced tumor delivery of engineered extracellular vesicles. , 2016, Biomaterials.

[19]  Keith L Ligon,et al.  Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell–derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity , 2013, Molecular therapy. Nucleic acids.

[20]  Tian Zhang,et al.  Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy , 2017, Nature Nanotechnology.

[21]  E. S. Day,et al.  Cancer Cell Membrane-Coated Nanoparticles for Cancer Management , 2019, Cancers.

[22]  M. Eblan,et al.  Clinical Translation of Nanomedicine. , 2015, Chemical reviews.

[23]  S. Simões,et al.  Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. , 2012, Accounts of chemical research.

[24]  Samir Mitragotri,et al.  Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies , 2014, Nature Reviews Drug Discovery.

[25]  A. Gaharwar,et al.  Engineered Extracellular Vesicles with Synthetic Lipids via Membrane Fusion to Establish Efficient Gene Delivery. , 2019, International journal of pharmaceutics.

[26]  J. Marchal,et al.  A versatile theranostic nanodevice based on an orthogonal bioconjugation strategy for efficient targeted treatment and monitoring of triple negative breast cancer. , 2020, Nanomedicine : nanotechnology, biology, and medicine.

[27]  Mauro Ferrari,et al.  Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.

[28]  C. Su,et al.  Design strategies and application progress of therapeutic exosomes , 2019, Theranostics.

[29]  Vladimir Torchilin,et al.  Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.

[30]  A. Lamprecht,et al.  Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin. , 2015, International journal of pharmaceutics.

[31]  E. Batrakova,et al.  Development and regulation of exosome-based therapy products. , 2016, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[32]  K. Peter,et al.  Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies. , 2017, Nanomedicine.

[33]  Aled Clayton,et al.  Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids , 2006, Current protocols in cell biology.

[34]  Asier Unciti-Broceta,et al.  Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis , 2019, Nature Catalysis.

[35]  F. Castellino,et al.  Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. , 2007, Blood.

[36]  Manho Kim,et al.  Low pH increases the yield of exosome isolation. , 2015, Biochemical and biophysical research communications.

[37]  E. Aboagye,et al.  Magnetic nanoparticles as contrast agents in the diagnosis and treatment of cancer. , 2013, Chemical Society reviews.

[38]  H. Daniel Ou-Yang,et al.  The influence of size, shape and vessel geometry on nanoparticle distribution , 2013, Microfluidics and nanofluidics.

[39]  Dennis E Discher,et al.  Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .

[40]  H. Gendelman,et al.  Specific Transfection of Inflamed Brain by Macrophages: A New Therapeutic Strategy for Neurodegenerative Diseases , 2013, PloS one.

[41]  Ronnie H. Fang,et al.  Nanoparticle biointerfacing via platelet membrane cloaking , 2015, Nature.

[42]  M. Pittenger,et al.  Concise Review: MSC‐Derived Exosomes for Cell‐Free Therapy , 2017, Stem cells.

[43]  S. Lai,et al.  Anti-PEG immunity: emergence, characteristics, and unaddressed questions. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[44]  V. Zharov,et al.  Circulating tumor cell identification by functionalized silver-gold nanorods with multicolor, super-enhanced SERS and photothermal resonances , 2014, Scientific Reports.

[45]  S. Lim,et al.  Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs , 2011, Journal of Translational Medicine.

[46]  Joshua L Hood.  Post isolation modification of exosomes for nanomedicine applications. , 2016, Nanomedicine.

[47]  J. Vandesompele,et al.  The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling , 2014, Journal of extracellular vesicles.

[48]  Qiang He,et al.  Stem Cell Membrane-Coated Nanogels for Highly Efficient In Vivo Tumor Targeted Drug Delivery. , 2016, Small.

[49]  R. Ramesh,et al.  Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer. , 2016, Journal of biomedical nanotechnology.

[50]  Mutsa P. Seremwe,et al.  A Comparative Study of Serum Exosome Isolation Using Differential Ultracentrifugation and Three Commercial Reagents , 2017, PloS one.

[51]  Tomasz Deptuch,et al.  Drug affinity and targeted delivery: double functionalization of silk spheres for controlled doxorubicin delivery into Her2-positive cancer cells , 2020, Journal of Nanobiotechnology.

[52]  Da Ma,et al.  Enhancing endosomal escape for nanoparticle mediated siRNA delivery. , 2014, Nanoscale.

[53]  P. Rai,et al.  Nanoparticle Design Strategies for Effective Cancer Immunotherapy. , 2017, Journal of Biomedicine.

[54]  Ronnie H. Fang,et al.  Cell Membrane Coating Nanotechnology , 2018, Advanced materials.

[55]  Gaurav Sahay,et al.  Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[56]  Hao Cheng,et al.  A Facile Approach to Functionalize Cell Membrane-Coated Nanoparticles , 2016, Theranostics.

[57]  P. Mishra,et al.  Metal nanoparticles: a theranostic nanotool against cancer. , 2015, Drug discovery today.

[58]  V. Rotello,et al.  Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles , 2011, PloS one.

[59]  Jie Zheng,et al.  Clearance Pathways and Tumor Targeting of Imaging Nanoparticles. , 2015, ACS nano.

[60]  K. Pienta,et al.  Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis , 2019, The Journal of experimental medicine.

[61]  M. Soleimani,et al.  Targeted delivery of doxorubicin to HER2 positive tumor models , 2019, International journal of nanomedicine.

[62]  J. Ryu,et al.  Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer , 2018, Gut and liver.

[63]  T. Maheswaran,et al.  Theranostics: A treasured tailor for tomorrow , 2014, Journal of pharmacy & bioallied sciences.

[64]  Richard J. Simpson,et al.  Proteomics Analysis of A33 Immunoaffinity-purified Exosomes Released from the Human Colon Tumor Cell Line LIM1215 Reveals a Tissue-specific Protein Signature* , 2009, Molecular & Cellular Proteomics.

[65]  M. Logozzi,et al.  Exosomes: the ideal nanovectors for biodelivery , 2013, Biological chemistry.

[66]  Wei Wei,et al.  Biomimetic Immuno‐Magnetosomes for High‐Performance Enrichment of Circulating Tumor Cells , 2016, Advanced materials.

[67]  Samuel A Wickline,et al.  Maximizing exosome colloidal stability following electroporation. , 2014, Analytical biochemistry.

[68]  Y. Pei,et al.  Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[69]  Kinam Park,et al.  Facing the truth about nanotechnology in drug delivery. , 2013, ACS nano.

[70]  Ronnie H. Fang,et al.  Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. , 2013, Nanoscale.

[71]  D. L. Cooper,et al.  Nanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity , 2014, Expert opinion on drug delivery.

[72]  Anne L. van de Ven,et al.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. , 2013, Nature nanotechnology.

[73]  T. Berg,et al.  Innate immune ‘self’ recognition: a role for CD47–SIRPα interactions in hematopoietic stem cell transplantation , 2008 .

[74]  J. Schorey,et al.  Ubiquitination as a Mechanism To Transport Soluble Mycobacterial and Eukaryotic Proteins to Exosomes , 2015, The Journal of Immunology.

[75]  K. Thiel,et al.  MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy. , 2019, Gynecologic oncology.

[76]  Shi Hu,et al.  CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity , 2019, Nature Communications.

[77]  Ronnie H. Fang,et al.  Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. , 2013, Nanoscale.

[78]  Jian-Bing Fan,et al.  miR-1289 and “Zipcode”-like Sequence Enrich mRNAs in Microvesicles , 2012, Molecular therapy. Nucleic acids.

[79]  V. Sanna,et al.  Targeted therapy using nanotechnology: focus on cancer , 2014, International journal of nanomedicine.

[80]  Ronnie H. Fang,et al.  Biomimetic strategies for targeted nanoparticle delivery , 2016, Bioengineering & translational medicine.

[81]  Z. Guan,et al.  Construction of targeting nanoparticle of 3',3''-bis-peptide-siRNA conjugate/mixed lipid with post-inserted DSPE-PEG2000-cRGD. , 2019, Molecular pharmaceutics.

[82]  R. Jain,et al.  Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors , 2011, Proceedings of the National Academy of Sciences.

[83]  K. Drescher,et al.  Exosomal miRNAs: Biological Properties and Therapeutic Potential , 2012, Front. Gene..

[84]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[85]  S. Kopetz,et al.  Platelets, circulating tumor cells, and the circulome , 2017, Cancer and Metastasis Reviews.

[86]  Chuan Yang,et al.  The effect of kinetic stability on biodistribution and anti-tumor efficacy of drug-loaded biodegradable polymeric micelles. , 2013, Biomaterials.

[87]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[88]  Lei Zhang,et al.  Softer zwitterionic nanogels for longer circulation and lower splenic accumulation. , 2012, ACS nano.